Merit Medical has revealed positive six-month data from a trial investigating its endoprosthesis in dialysis patients who ...

The trial compares Eli Lilly’s lutetium zadavotide guraxetan with Astellas’s Xtandi or Janssen’s Zytiga for mPRPC.

The Clinical Trials Arena team investigates assets in infectious diseases, metabolic disorders, oncology and ophthalmology.

Pfizer’s cancer cachexia candidate has provided patients with clinically meaningful weight gain in a Phase II trial, with the ...

As Ipsen pivots away from Cabometyx in mCRPC, US rights holder Exelixis will press ahead with a submission to the FDA.

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

Alio’s SmartPatch was cleared by the US FDA to measure multiple health metrics, including clinical markers, blood pressure ...

No drug specifically targets the underlying pathophysiological processes that cause sepsis and only symptomatic treatments ...

In the last couple of days at the European Association for the Study of Diabetes (EASD) 60th Annual Meeting 2024, the ...

Eli Lilly and Company has revealed positive topline results from the Phase III trials of efsitora alfa to treat adults with ...

Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.

Sanofi has reported that Phase III LIBERTY-CUPID Study C of Dupixent in patients with chronic spontaneous urticaria met ...